Eribis Pharmaceuticals

Eribis Pharmaceuticals AB develops drugs for the treatment of cardiovascular disorders, primarily acute myocardial ischemia and surgical

Eribis Pharmaceuticals AB develops drugs for the treatment of cardiovascular disorders, primarily acute myocardial ischemia and surgical preconditioning. Myocardial ischaemia is the pathological loss of or reduction in blood flow to a part of the muscular tissue of the heart. The company offers peptides, which are used in cardio and tissue protection, antihypoxia, and analgesia. Eribis Pharmaceuticals AB was founded in 2006 and is based in Uppsala, Sweden.